未知生产厂商
Brincidofovir is an oral lipid prodrug of cidofovir used in the treatment of human smallpox disease.
Brincidofovir is an oral lipid prodrug of cidofovir used in the treatment of human smallpox disease.
Brincidofovir is a pro-drug comprising cidofovir conjugated to a lipid molecule - the lipid component mimics an endogenous lipid, lysophosphatidylcholine, which allows the molecule to hijack endogenous lipid uptake pathways to enter infected cells. Following uptake, the lipid molecule is cleaved to generate cidofovir, which is then phosphorylated to generate the active antiviral compound, cidofovir disphosphate. The antiviral effects of cidofovir diphosphate appear to be the result of two distinct mechanisms. Mechanistic studies using recombinant vaccinia DNA polymerase suggest that it inhibits orthopoxvirus DNA polymerase-mediated DNA synthesis. In addition, cidofovir is an acyclic nucleotide analogue of deoxycytidine monophosphate - cidofovir diphosphate can therefore be incorporated into the growing viral DNA chain and consequently slow the rate of viral DNA synthesis.
Brincidofovir is indicated for the treatment of human smallpox disease in adult and pediatric patients.
共 1 项相关疾病
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。